Acetoacetic acid sodium salt is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. Acetoacetic acid sodium salt induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes.

Acetazolamide is a potent carbonic anhydrase (CA) inhibitor; best-studied agent for the amelioration of acute mountain sickness (AMS).

Acetanilide (Antifebrin)

Acemetacin is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.

Ac-DNLD-AMC is a fluorogenic caspase-3 substrate.

AC5 inhibitor C90 is a novel potent, selective adenylyl cyclase type 5 (AC5) inhibitor with IC50 of 30 nM, >5-fold selectivity over AC2 and AC6 subtypes.

AC-4-130 is a novel, potent STAT5 SH2 domain inhibitor, binds to and efficiently blocks STAT5 activation and subsequent transcriptional activity, shows high selectivity for STAT5 over STAT1 and STAT3.

ABTL0812 is a novel first-in-class, small molecule that inhibits the Akt/mTORC1 axis and shows antiproliferative effect on tumor cells.

ABT-288 is a potent, selective and competitive antagonist of H3 receptor with Ki of 1.9/8.2 nM for human/rat H3 respectively.

ABT-107 is a potent and selective α7 nAChR agonist with Ki of 0.2-0.6 nM for rat or human cortex α7 nAChRs.

ABT-102 is a potent, highly selective, orally active TRPV1 antagonist that inhibits agonist-evoked increases in intracellular Ca(2+) levels with IC50 of 5-7 nM.

ABT-100 (ABT100) is a highly selective, potent, orally bioavailable inhibitor of farnesyltransferase (FTase).

ABT-089 (Pozanicline) is a potent, selective α4β2 nAChR agonist with Ki of 16 nM.

ABT-080 is a potent FLAP inhibitor that inhibits ionophore-stimulated LTB(4) formation with with IC50 of 20 nM.

ABT-072 is a novel, orally bioavailable non-nucleoside HCV NS5B polymerase inhibitor with EC50 of 0.3 nM (GT1b).

Abn-CBD (Abnormal Cannabidiol) is a selective agonist of GPR55 receptor with EC50 of 2.5 uM, shows no significant activity against CB1 and CB2 receptors (EC50>30 uM).

ABMA is a novel broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite.

ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively..

Abeprazan is an acid pump inhibitor..

ABD345 is a small molecule inhibitor of RANKL signalling, inhibits TNF-induced NF-κB and MAPK activation and inflammation.

ABD-1970 (ABD1970) is a highly potent, selective Monoacylglycerol lipase (MGLL) inhibitor with IC50 of 13 nM (human MGLL).

AAL(S) is the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines by activating protein phosphatase 2A (PP2A)..

AAK1 inhibitor 25A is a potent, selective inhibitor of AAK1 and the closely related kinase BMP2K with Ki of 8 nM (AAK1).

AAK1 inhibitor 1 (SGC-AAK1-1) is a potent, selective inhibitor of AAK1 and BMP2K/BIKE ((BMP-2 inducible kinase)) that potently targets the ATP-binding site (AAK1 Ki =9.1 nM, BIKE Ki= 17 nM).

AAD777 (NVP-AAD777.

AA-861 (Docebenone) is a potent, selective 5-Lipoxygenase (5-LO) inhibitor with IC50 of 0.8 uM.

aA highly potent, selective, non-competitive and centrally active mGluR1 antagonist with Ki of 0.34 nM.

A-943931 is a potent, selective antagonist of histamine H4 receptor (H4R) with binding pKi of 8.33 and 8.42 for hH4 and rH4, respectively.

A-943931 dihydrochloride is a potent, selective antagonist of histamine H4 receptor (H4R) with binding pKi of 8.33 and 8.42 for hH4 and rH4, respectively.

A-836339 (A836339) is a potent and selective cannabinoid CB2 receptor agonist with Ki of 0.64 and 0.76 nM for human and rat CB2 receptors, displays 425- and 189-fold selectivity over CB1 receptor, respectively.